September 19, 2025
Jacob Sands, MD, provides a post hoc analysis of TROPION-Lung01, which showed improved intracranial activity and progression-free survival with datopotamab deruxtecan (Dato-DXd) versus docetaxel. Among patients with measurable brain metastases, Dato-DXd achieved a central nervous system confirmed overall response rate of 38%, with all evaluable patients showing disease control. No intracranial responses were seen in the docetaxel arm.
Related Posts
Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After Progression
Navigating Second-Line Treatment Decisions in EGFR+ NSCLC
Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC
